CANADIAN STROKE CONSORTIUM



The Canadian Stroke Consortium is a national academic network of neurologists and neuroscience researchers, many of whom are leading contributors to cerebrovascular research in Canada.

For further information contact

CSC National Headquarters

Telephone (416) 480-6775 Facsimile (416) 480-6032

E-Mail csc@srcl.sunnybrook.utoronto.ca
Web Site: http://sator.eric.on.ca:80/csc/cschome.html

Division of Neurology Department of Medicine

The Division of Neurology, Department of Medicine at Dalhousie University/QEII Health Sciences Centre wishes to recruit an academic neurologist with a special interest in neuromuscular disorders. The major proportion of the successful candidate's time will involve clinical aspects of neuromuscular disease and electrodiagnosis with the remainder spent in neuromuscular research and education of undergraduate medical students and residents.

The successful candidate will have completed training in Neurology, and will be certified with the Royal College of Physicians and Surgeons of Canada in Neurology. The applicant will preferably have spent one to two postgraduate years engaged in further training in neuromuscular disease and electrodiagnostic testing.

Dalhousie University in an employment equity/affirmative action employer. The University encourages applications from qualified women and men, aboriginal peoples, racial minorities and persons with disabilities. In accordance with Canadian Immigration requirements this advertisement is directed to Canadian citizens and permanent residents.

Send applications with up-to-date curriculum vitae and names of three references to:

Dr. R. Allan Purdy

Head, Division of Neurology
Dalhousie University Faculty of Medicine
Room 3024, New Halifax Infirmary
QEII Health Sciences Centre
Halifax, Nova Scotia
B3H 3A7

Applications will be accepted up to 30 days from date of this advertisement.

Academic Neurosurgeon Epilepsy and Functional Neurosurgery

The Toronto Hospital-University of Toronto seeks an academic neurosurgeon with experience in the surgical management of epilepsy and functional neurosurgical disorders. The preferred candidate should have both a strong track record in the surgery of these disorders and the basic neurobiology background required to develop a neural transplantation programme.

The division of Neurosurgery at The Toronto Hospital is staffed by 10 neurosurgeons and has a volume of over 2000 operative cases per year. There is an active residency and subspecialty fellowship program and extensive peer reviewed funding of neurosurgical laboratories. There is an epilepsy monitoring unit with an active team of investigators with expertise in epileptology, neuroimaging, neuropsychology, and in the cellular electrophysiology of epilepsy. The academic rank will be commensurate with the applicant's qualifications.

Send C.V. and cover letter before June 1, 1997 to:

Dr. Mark Bernstein

Head, Division of Neurosurgery
The Toronto Hospital
399 Bathurst Street
Toronto, Ontario
M5T 2S8
Tel: 416-603-6499

In accordance with employment equity policy, the University of Toronto encourages applications from qualified women and men, members of visible minorities, aboriginal peoples and persons with disabilities. In accordance with Canadian Immigration requirements, this advertisement is directed to Canadian citizens and permanent residents.

Vancouver Hospital and Health Sciences Centre Department of Pathology and Laboratory Medicine

NEUROPATHOLOGY POSITIONS

The Department of Pathology and Laboratory Medicine at the University of British Columbia has openings for two full-time faculty positions in Neuropathology at the junior faculty level. Responsibilities include service in Neuropathology, instruction of medical students and residents and participation in active basic or clinical research programs. In addition, strong research interest, diagnostic expertise and establishment of a high quality independent research program in neurodegenerative diseases are required for one of the positions. Review of applications will begin immediately to fill these positions available July 1, 1997.

In accordance with Canadian Immigration regulations, priority will be given to Canadian citizens and permanent residents. The successful candidate must be eligible for a medical license in the Province of British Columbia.

Qualified individuals should forward their letters of interest and intention as well as their curriculum vitae and the names of four references to:

Dr. Katerina Dorovini-Zis,
Head, Division of Neuropathology,
Department of Pathology & Laboratory Medicine,
899 West 12th Avenue,
Vancouver, British Columbia V5Z 1M9

Behavioural Neurology **Fellowship**

The Behavioural Neurology Program at Baycrest Centre for Geriatric Care invites applications for a one or two year fellowship beginning July 1, 1997.

The fellowship will offer clinical and research training in the cognitive neurology of degenerative disease, stroke, and neuropsychiatric disorders.

For further information, please contact: Morris Freedman, M.D., Director, Behavioural Neurology Program, Baycrest Centre for Geriatric Care. Room 4W36, 3560 Bathurst Street, Toronto, Ontario, Canada M6A 2E1 e-mail: morris.freedman@utoronto.ca

The Anne and Max Tanenbaum Chair in Molecular/Cellular Neuroscience Research at The Toronto Hospital

Funded by an endowment from Anne Tanenbaum, a Joint Chair program in biomedical research has been established by the University of Toronto in cooperation with The Toronto Hospital, the Baycrest Centre for Geriatric Care, The Hospital for Sick Children, and Mount Sinai Hospital to honour Anne and Max Tanenbaum. The endowed Chair at The Toronto Hospital will be awarded to an outstanding researcher with potential for leadership and who has international recognition in a relevant area of neuroscience. The Toronto Hospital houses the largest clinical Neurosciences Centre in Canada. Neuroscience research, comprising over 40 principal investigators in basic and clinical sciences at The Toronto Hospital, is one of the priority research programs of the Hospital and the University of Toronto. The Neurosciences Centre has strengths and interests in the following fields; neuroprotection, stroke, epilepsy, CNS trauma including spinal cord injury, neuroimmunology, aging, neuro-oncology, movement disorders, neuromodelling, systems neuroscience.

For the Tanenbaum Chair in Molecular/Cellular Neuroscience, adequate resources in space and funding will be provided to facilitate a world-class program in cellular and molecular neurobiology. The Chair will also lead in the recruitment of 3 or more cellular/molecular neuroscientists for this program.

The Toronto Hospital encourages applications from qualified women and men, members of visible minorities, aboriginal peoples and persons with disabilities. In accordance with Canadian Immigration requirements, this advertisement is directed first to Canadian citizens and permanent residents.

Applicants should submit, along with a covering letter describing current research interests and future research goals, a C.V., relevant reprints, and have three letters of reference sent independently by June 1, 1997 to:

> Dr. Donald S. Layne Vice President, Research The Toronto Hospital 200 Elizabeth Street Toronto, Ontario CANADA M5G 2C4 Tel: (416) 340-4561 Fax: (416) 340-4596

Claude Bertrand Fellowship in Neurosurgical Research

The Division of Neurosurgery at Notre-Dame Hospital affiliated with the University of Montreal is offering a one year fellowship to conduct independent clinical and/or basic sciences investigation in neurosurgery. The fellowship will start on January 12th, 1998.

- Pre-requisites: completion training in neurology, neurosurgery or advanced degree in neurosciences.
- The applicant must submit a detailed abstract of his research project as well as a Curriculum Vitae.
- Stipend \$35,000.00 Can.
- Application deadline: July 31, 1997.

Send applications to:

Michel W. Bojanowski, MD, FRCS(C) Claude Bertrand Fellowship in Neurosurgical Research Division of Neurosurgery Notre-Dame Hospital 1560 Sherbrooke Street East Montreal, Quebec H2L 4M1

ADVERTISERS INDEX

Abbott

Epival - ifc, xxix, xxx

Astro-Med

Grass® Neurodata system - xx

Betaseron – viii, ix, xxxiii, xxxiv

Glaxo Wellcome

Imitrex - xiv, xv, xxxix

Lamictal – iv, v, xvi, xvii, xxxv, xxxvi

Hoechst Marion Roussel

Frisium - ibc, xxviii, xli

Sabril – iii, x, xi

Janssen – Ortho

Topomax - vi, vii, xxii, xxiii, xxxvii,

xxxviii, xxxix

Novartis Pharma Canada Inc.

Migranal – xviii, xix, xxi, obc, xxxii


Tegretol – xxvi, xxvii

Parke Davis

Neurontin - xiii, xxiv, xxv, xl

Classified Ads

- xli, xlii, xliii



ÉPILEPSIE

Lorsque l'objectif thérapeutique est la maîtrise complète des crises

Maîtrise complète des crises chez un pourcentage impressionnant de patients¹

Frisium est « un antiépileptique remarquablement efficace et [généralement] sûr d'emploi lorsqu'il est ajouté au traitement »¹

Efficace contre tous les types de crises, tant chez les adultes que chez les enfants²

Prise uniquotidienne, de préférence au coucher[†]

LARGE SPECTRE D'ACTION

Frisium®

Une fois par jourt

† La dose quotidienne peut être fractionnée chez certains patients.

Frisium est indiqué comme traitement d'appoint chez les patients épileptiques dont l'état n'est pas maîtrisé de façon satisfaisante par le traitement antiépileptique utilisé. À l'instar des autres benzodiazépines, le clobazam doit être administré avec prudence aux patients, notamment aux personnes âgées. Les effets indésirables les plus fréquents (>1 %) comprennent la somnolence, les étourdissements, la fatique, l'ataxie, le gain pondéral, la nervosité, les troubles du comportement, l'hostilité et la vision brouillée.

Hoechst Marion Roussel

Hoechst Marion Roussel Canada Inc., Laval (Québec) H7L 4A8 Une société du Groupe Hoechst




®Marque déposée de Hoechst AG, Allemagne, utilisée sous licence par Hoechst Marion Roussel Canada Inc., Laval (Québec) H7L 4A8.

CCPP ACIM FRI 96012 F

Pour documentation voir page xli.

Introducing MIGRANAL Nasal Spray



A 5-HT₁ agonist that starts fast and offers long-lasting relief from migraine

5-HT, agonist therapy

- MIGRANAL relieves migraine headaches and associated symptoms¹
- · Nasal administration bypasses the GI tract

Fast onset of relief

- Can be taken at any stage of the migraine 1,0
- Clinical response begins within 30 minutes¹
- MIGRANAL relieved up to 70% of migraines at 4 hours (n=105)^{2,†}

Long-lasting relief^{††}

- Long half-life: 10 hours¹
- 85% of responders had no return of migraine within 24 hours after taking MIGRANAL (n=73)²
- Therefore, MIGRANAL may help avoid the need for repeated dosing, rescue medication, and the associated costs.

Generally well-tolerated in clinical trials¹

- Most common adverse events were transient and self-limiting, and may be attributable to the route of administration ^{2,3}: Rhinitis (25% incidence) reported as rhinitis, rhinorrhea, nasal/nose congestion, dryness, edema and excessive sneezing; other side effects observed included: nausea (9%), taste disturbance (7%) and vomiting (4%).
 - \Diamond For best results, treatment should be initiated at the first sign/symptom of a migraine attack.
 - † Relief = from moderate/severe pain to mild/no pain
 - †† Up to 24 hours with a single 2 mg dose
 - MIGRANAL is contraindicated in patients predisposed to vasospastic reactions. Please see Prescribing Information for more details.





Fast migraine relief that lasts



*Registered trademark

MIG-96-10-3531E

A SANDOZ

SANDOZ CANADA INC.